natgillin/translations-raw huggingface dataset:
Therapeutic experience is limited in patients with mild to moderate renal impairment (see section 4.4). 
Terapijsko iskustvo u bolesnika s blagim do umjerenim oštećenjem funkcije bubrega je ograničeno (vidjeti dio 4.4.).
DuoPlavin 75 mg/75 mg film-coated tablets Aluminium blisters in cardboard cartons containing 14, 28, 30 and 84 film-coated tablets. 
DuoPlavin 75 mg/75 mg filmom obložene tablete 14, 28, 30 i 84 filmom obloženih tableta u aluminijskim blisterima, u kartonskoj kutiji.
- Tablet core: mannitol (E421), macrogol 6000, microcrystalline cellulose, low substituted hydroxypropylcellulose, maize starch, hydrogenated castor oil (see section 2 ‘DuoPlavin contains hydrogenated castor oil'), stearic acid and colloidal anhydrous silica - Tablet coating: lactose monohydrate (see section 2 ‘DuoPlavin contains lactose'), hypromellose (E464), titanium dioxide (E171), triacetin (E1518), yellow iron oxide (E172) - Polishing agent: carnauba wax 
Drugi sastojci su: - Jezgra tablete: manitol (E421), makrogol 6000, mikrokristalična celuloza, nisko supstituirana hidroksipropilceluloza, kukuruzni škrob, hidrogenirano ricinusovo ulje (vidjeti dio 2. "DuoPlavin sadrži hidrogenirano ricinusovo ulje"), stearatna kiselina i koloidni, bezvodni silicijev dioksid - Ovojnica tablete: laktoza hidrat (vidjeti dio 2. "DuoPlavin sadrži laktozu"), hipromeloza (E464), titanijev dioksid (E171), triacetin (E1518), žuti željezov oksid (E172) - Sredstvo za poliranje: karnauba vosak
The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel plus ASA group and 1,187 (18.8%) in the ASA group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel plus ASA group. 
U skupini koja je primala klopidogrel plus ASK bilo je 1035 (16,5%) bolesnika sa koprimarnim ishodom (smrt zbog kardiovaskularnih uzroka, infarkt miokarda, moždani udar ili refraktorna ishemija), odnosno 1187 (18,8%) bolesnika u skupini koja je primala samo ASK, što znači smanjenje relativnoga rizika od 14% (95% CI: 6%-21%, p=0,0005) u skupini koja je primala klopidogrel plus ASK.
DuoPlavin has no or negligible influence on the ability to drive and use machines. 
4.7 Utjecaj na sposobnost upravljanja vozilima i rada sa strojevima DuoPlavin ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
The ASA in DuoPlavin is rapidly hydrolyzed in plasma to salicylic acid, with a half-life of 0.3 to 0.4 hours for ASA doses from 75 to 100 mg. Salicylic acid is primarily conjugated in the liver to form salicyluric acid, a phenolic glucuronide, an acyl glucuronide, and a number of minor metabolites. 
ASK iz DuoPlavina brzo se u plazmi hidrolizira u salicilatnu kiselinu koja ima poluvijek od 0,3-0,4 sata za doze ASK od 75 do 100 mg.
Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis, non-cardiogenic pulmonary edema with chronic use and in the context of a hypersensitivity reaction due to acetylsalicylic acid*, eosinophilic pneumonia. 
Poremećaji dišnog sustava, prsišta i sredoprsja epistaksa krvarenje u dišnome sustavu (hemoptiza, plućno krvarenje), bronhospazam, intersticijski pneumonitis, nekardiogeni edem pluća pri kroničnoj primjeni i u sklopu reakcije preosjetljivosti na acetilsalicilatnu kiselinu*, eozinofilna pneumonija
• swelling in the mouth or skin disorders such as rashes and itching, blisters of the skin. 
• oticanje u ustima ili kožne poremećaje kao što su osip i svrbež te mjehurići na koži; ovi simptomi mogu biti znakovi alergijske reakcije.
Clopidogrel must be metabolised by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. 
Da bi nastao taj aktivni metabolit, klopidogrel se mora metabolizirati pomoću enzima CYP450.
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), bone marrow failure*, aplastic anaemia, pancytopenia, bicytopenia*, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia, haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency* (see section 4.4) 
Poremećaji krvi i limfnog sustava trombocitopenija, leukopenija, eozinofilija neutropenija, uključujući tešku neutropeniju trombotična trombocitopenična purpura (TTP) (vidjeti dio 4.4.), zatajenje koštane srži*, aplastična anemija, pancitopenija, bicitopenija*, agranulocitoza, teška trombocitopenija, stečena hemofilija A, granulocitopenija, anemija, hemolitička anemija u bolesnika s nedostatkom glukoza-6fosfat dehidrogenaze (G6PD)* (vidjeti dio
DuoPlavin 75 mg/75 mg film-coated tablets (tablets) are oval, slightly biconvex, yellow, engraved on one side with ‘C75' and ‘A75'on the other side. 
DuoPlavin 75 mg/75 mg filmom obložene tablete (tablete) su ovalne, blago bikonveksne, žute tablete s utisnutom oznakom "C75" na jednoj i "A75" na drugoj strani.
DuoPlavin 75 mg/75 mg film-coated tablets DuoPlavin should be given as a single daily 75 mg/75 mg dose. 
DuoPlavin 75mg/75 mg filmom obložene tablete DuoPlavin se daje u jednokratnoj dnevnoj dozi od 75 mg/75 mg.
You should stop other clopidogrel treatment while you are taking DuoPlavin. 
Dok uzimate DuoPlavin, trebate prekinuti drugu terapiju klopidogrelom.
DuoPlavin 75 mg/100 mg film-coated tablets DuoPlavin should be given as a single daily 75 mg/100 mg dose. 
DuoPlavin 75mg/100 mg filmom obložene tablete DuoPlavin se daje u jednokratnoj dnevnoj dozi od 75 mg/100 mg.
EU/1/10/619/008 14 film-coated tablets EU/1/10/619/009 28 film-coated tablets EU/1/10/619/010 30x1 film-coated tablet EU/1/10/619/011 50x1 film-coated tablet EU/1/10/619/012 84 film-coated tablets EU/1/10/619/013 90x1 film-coated tablet EU/1/10/619/014 100x1 film-coated tablet 
EU/1/10/619/008 14 filmom obloženih tableta EU/1/10/619/009 28 filmom obloženih tableta EU/1/10/619/010 30x1 filmom obloženih tableta EU/1/10/619/011 50x1 filmom obloženih tableta EU/1/10/619/012 84 filmom obloženih tableta EU/1/10/619/013 90x1 filmom obloženih tableta EU/1/10/619/014 100x1 filmom obloženih tableta
DuoPlavin 75 mg/75 mg film-coated tablets EU/1/10/619/001 - Cartons of 14 film-coated tablets in aluminium blister packs EU/1/10/619/002 - Cartons of 28 film-coated tablets in aluminium blister packs EU/1/10/619/003 - Cartons of 30x1 film-coated tablet in aluminium blister packs EU/1/10/619/004 - Cartons of 50x1 film-coated tablet in aluminium blister packs EU/1/10/619/005 - Cartons of 84 film-coated tablets in aluminium blister packs EU/1/10/619/006 - Cartons of 90x1film-coated tablet in aluminium blister packs EU/1/10/619/007 - Cartons of 100x1film-coated tablet in aluminium blister packs EU/1/10/619/015 - Cartons of 30 film-coated tablet in aluminium blister packs 
DuoPlavin 75 mg/75 mg filmom obložene tablete EU/1/10/619/001 - kutije s 14 filmom obloženih tableta u aluminijskim blisterima EU/1/10/619/002 - kutije s 28 filmom obloženih tableta u aluminijskim blisterima EU/1/10/619/003 - kutije s 30x1 filmom obloženih tableta u aluminijskim blisterima EU/1/10/619/004 - kutije s 50x1 filmom obloženih tableta u aluminijskim blisterima EU/1/10/619/005 - kutije s 84 filmom obložene tablete u aluminijskim blisterima EU/1/10/619/006 - kutije s 90x1 filmom obloženih tableta u aluminijskim blisterima EU/1/10/619/007 - kutije sa 100x1 filmom obloženih tableta u aluminijskim blisterima EU/1/10/619/015 - kutije s 30 filmom obloženih tableta u aluminijskim blisterima
DuoPlavin 75 mg/75 mg film-coated tablets DuoPlavin 75 mg/100 mg film-coated tablets 
DuoPlavin 75 mg/75 mg filmom obložene tablete DuoPlavin 75 mg/100 mg filmom obložene tablete
EU/1/10/619/001 14 film-coated tablets EU/1/10/619/002 28 film-coated tablets EU/1/10/619/003 30x1 film-coated tablet EU/1/10/619/004 50x1 film-coated tablet EU/1/10/619/005 84 film-coated tablets EU/1/10/619/006 90x1 film-coated tablet EU/1/10/619/007 100x1 film-coated tablet EU/1/10/619/015 30 film-coated tablets 
EU/1/10/619/001 14 filmom obloženih tableta EU/1/10/619/002 28 filmom obloženih tableta EU/1/10/619/003 30x1 filmom obloženih tableta EU/1/10/619/004 50x1 filmom obloženih tableta EU/1/10/619/005 84 filmom obloženih tableta EU/1/10/619/006 90x1 filmom obloženih tableta EU/1/10/619/007 100x1 filmom obloženih tableta EU/1/10/619/015 30 filmom obloženih tableta
DuoPlavin 75 mg/100 mg film-coated tablets (tablets) are oval, slightly biconvex, light pink, engraved on one side with ‘C75' and ‘A100'on the other side. 
DuoPlavin 75 mg/100 mg filmom obložene tablete Svijetloružičaste, ovalne, blago bikonveksne tablete, s utisnutim oznakama "C75" na jednoj i "A100" na drugoj strani.
DuoPlavin 75 mg/100 mg film-coated tablets EU/1/10/619/008 - Cartons of 14 film-coated tablets in aluminium blister packs EU/1/10/619/009 - Cartons of 28 film-coated tablets in aluminium blister packs EU/1/10/619/010 - Cartons of 30x1 film-coated tablet in aluminium blister packs EU/1/10/619/011 - Cartons of 50x1 film-coated tablet in aluminium blister packs EU/1/10/619/012 - Cartons of 84 film-coated tablets in aluminium blister packs EU/1/10/619/013 - Cartons of 90x1 film-coated tablet in aluminium blister packs EU/1/10/619/014 - Cartons of 100x1 film-coated tablet in aluminium blister packs 
DuoPlavin 75 mg/100 mg filmom obložene tablete EU/1/10/619/008 - kutije s 14 filmom obloženih tableta u aluminijskim blisterima EU/1/10/619/009 - kutije s 28 filmom obloženih tableta u aluminijskim blisterima EU/1/10/619/010 - kutije s 30x1 filmom obloženih tableta u aluminijskim blisterima EU/1/10/619/011 - kutije s 50x1 filmom obloženih tableta u aluminijskim blisterima EU/1/10/619/012 - kutije s 84 filmom obložene tablete u aluminijskim blisterima EU/1/10/619/013 - kutije s 90x1 filmom obloženih tableta u aluminijskim blisterima EU/1/10/619/014 - kutije sa 100x1 filmom obloženih tableta u aluminijskim blisterima
DuoPlavin 75 mg/75 mg film-coated tablets DuoPlavin 75 mg/100 mg film-coated tablets clopidogrel/acetylsalicylic acid 
DuoPlavin 75 mg/75 mg filmom obložene tablete DuoPlavin 75 mg/100 mg filmom obložene tablete klopidogrel/acetilsalicilatna kiselina
DuoPlavin 75 mg/75 mg film-coated tablets 
DuoPlavin 75 mg/75 mg filmom obložene tablete
DuoPlavin 75 mg/100 mg film-coated tablets 
DuoPlavin 75 mg/100 mg filmom obložene tablete
If you take more DuoPlavin than you should 
Dok uzimate DuoPlavin, ne biste smjeli dojiti.
Hydrogenated castor oil Stearic acid 
DuoPlavin sadrži hidrogenirano ricinusovo ulje
Gynaecomastia 
Nikorandil
Each tablet contains: 75 mg of clopidogrel (as hydrogen sulphate) and 100 mg of acetylsalicylic acid. 
Jedna tableta sadrži: 75 mg klopidogrela (u obliku klopidogrelhidrogensulfata) i 100 mg acetilsalicilatne kiseline.
Each tablet contains: 75 mg of clopidogrel (as hydrogen sulphate) and 75 mg of acetylsalicylic acid. 
Jedna tableta sadržava: 75 mg klopidogrela (u obliku klopidogrelhidrogensulfata) i 75 mg acetilsalicilatne kiseline.
Each tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 75 mg of acetylsalicylic acid. 
Jedna tableta sadržava 75 mg klopidogrela (u obliku klopidogrelhidrogensulfata) i 75 mg acetilsalicilatne kiseline.
• paclitaxel, medicine to treat cancer, 
o oralne antikoagulanse, lijekove koji sprječavaju zgrušavanje krvi,
DuoPlavin 75 mg/100 mg film-coated tablets clopidogrel/acetylsalicylic acid 
DuoPlavin 75 mg/100 mg filmom obložene tablete klopidogrel/acetilsalicilatna kiselina
Each tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 100 mg of acetylsalicylic acid. 
Jedna tableta sadržava 75 mg klopidogrela (u obliku klopidogrelhidrogensulfata) i 100 mg acetilsalicilatne kiseline.
DuoPlavin 75 mg/75 mg film-coated tablets clopidogrel/acetylsalicylic acid 
DuoPlavin 75 mg/75 mg filmom obložene tablete klopidogrel/acetilsalicilatna kiselina
NAME OF THE MEDICINAL PRODUCT DuoPlavin 75 mg/100 mg tablets clopidogrel/acetylsalicylic acid 
DuoPlavin 75 mg/100 mg tablete klopidogrel/acetilsalicilatna kiselina
• probenecid, benzbromarone, or sulfinpyrazone, medicines used to treat gout, 
Prijavljene su interakcije sa sljedećim lijekovima: Urikozurici (benzbromaron, probenecid, sulfinpirazon)
NAME OF THE MEDICINAL PRODUCT DuoPlavin 75 mg/75 mg tablets clopidogrel/acetylsalicylic acid 
DuoPlavin 75 mg/75 mg tablete klopidogrel/acetilsalicilatna kiselina
Macrogol 6000 
6.3 Rok valjanosti
DuoPlavin 75 mg/100 mg film-coated tablets Aluminium blisters in cardboard cartons containing 14, 28 and 84 film-coated tablets. 
14, 28 i 84 filmom obloženih tableta u aluminijskim blisterima, u kartonskoj kutiji.
Concentrate for solution for 
Koncentrat za otopinu za infuziju
Pack size 
EU broj
ATC Code: G04BE03. 
ATK oznaka: G04BE03.
− Get in a semi-sitting position and try to relax 
- Zauzmite polusjedeći položaj i pokušajte se opustiti
- If you are taking riociguat. 
• Ako uzimate riociguat.
These measures will help protect the environment. 
Ove će mjere pomoći u zaštiti okoliša.
In cases of overdose, standard supportive measures should be adopted as required. 
U slučajevima predoziranja, po potrebi treba primijeniti standardne suportivne mjere.
• This medicine has been prescribed for you only. 
• Ovaj je lijek propisan Vama.
Sildenafil Teva can be taken with or without food. 
Sildenafil Teva se može uzeti sa ili bez hrane.
Sildenafil Teva with food and drink and alcohol 
Sildenafil Teva s hranom, pićem i alkoholom
− If you have recently had a stroke or a heart attack, or if you have low blood pressure. 
• Ako ste nedavno imali moždani ili srčani udar ili ako imate nizak krvni tlak.
− If you have certain rare inherited eye diseases (such as retinitis pigmentosa). 
• Ako imate određene rijetke nasljedne bolesti oka (kao što je retinitis pigmentosa).
Elderly Dosage adjustments are not required in elderly patients (≥ 65 years old). 
Starije osobe Prilagodbe doziranja u starijih bolesnika nisu neophodne (≥ 65 godina starosti).
Date of first authorisation: 30 November 2009 Date of latest renewal: 09 September 2014 
Datum posljednje obnove: 09. rujna 2014.
− Do not use nitrates to treat your chest pain 
- Nemojte uzimati nitrate za liječenje bolova u prsima
Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu 
Detaljnije informacije o ovom lijeku dostupne su na web stranici Europske agencije za lijekove http://www.ema.europa.eu/.
2031GA HaarlemThe Netherlands 
2031GA Haarlem Nizozemska
− If you have a deformity of your penis or Peyronie's Disease. 
• Ako imate deformaciju penisa ili Peyronijevu bolest.
In clinical trials sildenafil was administered to more than 8000 patients aged 19-87. 
U kliničkim ispitivanjima, sildenafil je primijenjen kod više od 8000 bolesnika u dobi 19-87 godina.
− If you have problems with your heart. 
• Ako imate poteškoće sa srcem.
The mean absolute oral bioavailability is 41 % (range 25-63 %). 
Srednja apsolutna oralna bioraspoloživost iznosi 41% (raspon 25-63%).
The amount of time Sildenafil Teva takes to work varies from person to person, but it normally takes between half an hour and one hour. 
Vrijeme potrebno za početak djelovanja lijeka Sildenafil Teva razlikuje se od osobe do osobe, ali se obično kreće između pola sata i jednog sata.
Very common (may affect more than 1 in 10 people): headache 
Vrlo često (može se javiti kod više od 1 na 10 osoba): glavobolja.
What Sildenafil Teva is and what it is used for 
Što je Sildenafil Teva i za što se koristi
Mean pulmonary systolic blood pressure decreased by 9 %. 
Srednji pulmonalni sistolički krvni tlak se snizio za 9%.
Plasma concentrations of this metabolite are approximately 40 % of those seen for sildenafil. 
Koncentracije ovog metabolita u plazmi iznose približno 40% od onih opaženih za sildenafil.
Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to reproduction and development. 
Neklinički podaci nisu ukazali na posebne rizike za ljude temeljem konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti ponovljenih doza, genotoksičnosti, karcinogenog potencijala i reproduktivne i razvojne toksičnosti.
If you are taking riociguat or are unsure, tell your doctor. 
Ako uzimate riociguat ili niste sigurni, obratite se svom liječniku.
Because not all adverse reactions are reported to the Marketing Authorisation Holder and included in the safety database, the frequencies of these reactions cannot be reliably determined. 
obzirom da sve nuspojave nisu prijavljene nositelju odobrenja i nisu uključene u bazu podataka o sigurnosti primjene lijeka, učestalost tih nuspojava nije moguće pouzdano odrediti.
If you take more Sildenafil Teva than you should: 
Ako uzmete više lijeka Sildenafil Teva nego što ste trebali:
You should take Sildenafil Teva about one hour before you plan to have sex. 
Sildenafil Teva trebate uzeti oko jedan sat prije planirane spolne aktivnosti.
The recommended starting dose is 50 mg. 
Preporučena početna doza iznosi 50 mg.
Sildenafil Teva will only help you to get an erection if you are sexually stimulated. 
Sildenafil Teva će Vam pomoći u postizanju erekcije jedino ako ste seksualno stimulirani.
You should not take Sildenafil Teva if you are a woman. 
Ne smijete uzimati Sildenafil Teva ako ste žena.
(IC50 > 150 μM). 
>150 µM).
Contents of the pack and other information What Sildenafil Teva contains 
Sadržaj pakiranja i druge informacije Što Sildenafil Teva sadrži
In controlled clinical trials, the discontinuation rate due to sildenafil was low and similar to placebo. 
kontroliranim kliničkim ispitivanjima, stopa odustalih zbog sildenafila bila je niska i slična placebu.
You should not take Sildenafil Teva more than once a day. 
Sildenafil Teva se ne smije uzimati više od jednom dnevno.
Talk to your doctor, pharmacist or nurse before taking Sildenafil Teva 
Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego uzmete Sildenafil Teva
If you are taking medicines known as protease inhibitors, such as for the treatment of HIV, your doctor may start you on the lowest dose (25 mg) of Sildenafil Teva. 
Ako uzimate lijekove poznate kao inhibitori proteaze, na primjer za liječenje infekcije HIV-om, liječnik Vam može propisati najnižu početnu dozu (25 mg) lijeka Sildenafil Teva.
Sildenafil Teva tablets may interfere with some medicines, especially those used to treat chest pain. 
Sildenafil Teva tablete mogu međusobno djelovati s nekim lijekovima, osobito onima koji se koriste za liječenje boli u prsima.
The active substance is sildenafil. 
Djelatna tvar je sildenafil.
In the table below all medically important adverse reactions, which occurred in clinical trials at an incidence greater than placebo are listed by system organ class and frequency (very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000). 
U donjoj tablici navedene su sve medicinski značajne nuspojave, koje su se javile u kliničkim ispitivanjima s učestalošću većom nego kod placeba, razvrstane prema organskim sustavima i učestalosti (vrlo često (≥1/10), često (≥1/100 do <1/10), manje često (≥1/1000 do <1/100), rijetko (≥1/10 000 do <1/1 000).
After a single oral dose of 100 mg, the mean maximum total plasma concentration of sildenafil is approximately 440 ng/mL(CV 40 %). 
Nakon jednokratne oralne doze od 100 mg, srednja maksimalna ukupna koncentracija sildenafila u plazmi iznosi približno 440 ng/ml (CV 40%).
Sildenafil Teva is a treatment for adult men with erectile dysfunction, sometimes known as impotence. 
Sildenafil Teva je namijenjen liječenju odraslih muškaraca s erektilnom disfunkcijom, ponekad poznatom pod nazivom impotencija.
Renal dialysis is not expected to accelerate clearance as sildenafil is highly bound to plasma proteins and not eliminated in the urine. 
Ne očekuje se da renalna dijaliza ubrza klirens, jer je sildenafil u velikoj mjeri vezan na proteine plazme i urinom se ne eliminira.
Sildenafil Teva is indicated in adult men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. 
Sildenafil Teva je indiciran u odraslih muškaraca s erektilnom disfunkcijom, odnosno nemogućnošću postizanja ili održavanja penilne erekcije dostatne za zadovoljavajuću seksualnu aktivnost.
To get the maximum benefit from your medicine, you are advised not to drink excessive amounts of alcohol before taking Sildenafil Teva. 
Kako biste imali najviše koristi od lijeka, savjetuje se da ne uzimate veće količine alkohola prije uzimanja lijeka
Pharmacotherapeutic group: Urologicals; Drugs used in erectile dysfunction. 
Farmakoterapijska skupina: urološki preparati; lijekovi koji se primjenjuju kod erektilne disfunkcije.
This is most likely to happen within 4 hours after taking Sildenafil Teva. 
Do toga će najvjerojatnije doći unutar 4 sata nakon uzimanja lijeka Sildenafil Teva.
Adverse reactions from post-marketing surveillance has been gathered covering an estimated period >10 years. 
Nuspojave nakon stavljanja u promet prikupljene su u razdoblju procijenjenom na > 10 godina.
Do not take Sildenafil Teva with other medicines unless your doctor tells you that you can. 
Sildenafil Teva s drugim lijekovima, osim ako Vam tako nije rekao liječnik.
Patients should be advised that in the event of any sudden visual defect, they should stop taking Sildenafil Teva and consult a physician immediately (see section 4.3). 
Bolesnike treba savjetovati da u slučaju iznenadnog poremećaja vida prestanu uzimati Sildenafil Teva i odmah zatraže savjet liječnika (vidjeti dio 4.3).
Your doctor may start you on a lower dose (25 mg) of Sildenafil Teva. 
Liječnik Vas može staviti na početnu nižu dozu (25 mg) lijeka Sildenafil Teva.
Sildenafil Teva can cause dizziness and can affect vision. 
Sildenafil Teva može uzrokovati omaglicu i utjecati na vid.
The other ingredients are: 
Ostale nuspojave:
− If you have a severe heart or liver problem. 
• Ako imate teške probleme sa srcem ili jetrom.
As dizziness and altered vision were reported in clinical trials with sildenafil, patients should be aware of how they react to Sildenafil Teva, before driving or operating machinery. 
Budući da su omaglica i poremećaj vida zabilježeni u kliničkim ispitivanjima sa sildenafilom, bolesnici moraju uzeti u obzir način na koji oni reagiraju na Sildenafil Teva, prije upravljanja vozilima ili rada sa strojevima.
What Sildenafil Teva is and what it is used for What you need to know before you take Sildenafil Teva How to take Sildenafil Teva Possible side effects 
Što je Sildenafil Teva i za što se koristi Što morate znati prije nego počnete uzimati Sildenafil Teva Kako uzimati Sildenafil Teva
If Sildenafil Teva is taken with food, the onset of activity may be delayed compared to the fasted state (see section 5.2). 
Ako se Sildenafil Teva uzima s hranom, nastup djelovanja može biti odgođen u usporedbi s uzimanjem natašte (vidjeti dio 5.2).
What Sildenafil Teva looks like and contents of the pack 
Kako Sildenafil Teva izgleda i sadržaj pakiranja
In vitro studies: Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 
In vitro ispitivanja: Sildenafil je slabi inhibitor citokroma P450 izoformi 1A2, 2C9, 2C19, 2D6, 2E1 i 3A4 (IC50
In order for Sildenafil Teva to be effective, sexual stimulation is required. 
Kako bi Sildenafil Teva djelovao, neophodna je seksualna stimulacija.
If you feel that the effect of Sildenafil Teva is too strong or too weak, talk to your doctor or pharmacist. 
Ako osjećate da je učinak Sildenafil Teva prejak ili preslab, obratite se svom liječniku ili ljekarniku.
When sildenafil is taken with food, the rate of absorption is reduced with a mean delay in tmax of 60 minutes and a mean reduction in Cmax of 29 %. 
Prilikom uzimanja sildenafila s hranom, brzina apsorpcije je smanjena sa srednjom odgodom tmax od 60 minuta i srednjim smanjenjem Cmax od 29%.